/
Metabolic & Endocrine
Obesity & Overweight
15
Pipeline Programs↗
65
Active Trials↗
19
Companies Involved↗
Obesity & Overweight is an emerging landscape with 15 programs across 19 companies. The most active players are AstraZeneca, Lumos Pharma, Corxel Pharmaceuticals. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical6
Phase 26
Phase 31
Approved
No programs
Analysis
Modality Breakdown
77%
Small molecule
10 of 13 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 13 classified programs, each share of the total. Modality classified for 87% of 15 pipeline programs.
Analysis
Trial Status
75
clinical trials
Not yet recruiting32 · 43%
Recruiting26 · 35%
Completed10 · 13%
Active, not recruiting6 · 8%
Enrolling by invitation1 · 1%
Clinical Trials
Trial Activity
75 trials
High-intensity Interval Training Under Hypoxic Versus Normoxic Conditions: Effects on Fat Mass Loss and Gut Microbiota in Adults Aged 50-75 With Overweight or Obesity
Recruiting·LLaboratoire des Adaptations Métaboliques à l'Exercice en conditions Physiologiques et Pathologiques·Preclinical·NCT07796971·32 enrolled
Adjunctive Transcutaneous Auricular Vagus Nerve Stimulation in Overweight or Obese Patients With a Suboptimal Weight-Loss Response to Incretin Receptor Agonists: A Single-Center, Randomized, Sham-Controlled Study
Recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Preclinical·NCT07619989·24 enrolled
Page 1 of 5
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)